REDITUX 100MG INJ

About

REDITUX 100MG INJ is a biosimilar formulation of Rituximab, a monoclonal antibody designed to specifically target the CD20 antigen found on the surface of normal and malignant B-lymphocytes. Its therapeutic action involves binding to CD20, which triggers a series of immune-mediated events, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis, ultimately leading to the selective depletion of CD20-positive B cells. This targeted depletion is highly effective in managing various B-cell mediated disorders, both cancerous and autoimmune. The 100 mg injection is typically administered intravenously in a controlled clinical setting.

Rituximab's ability to selectively remove B cells makes it a cornerstone in the treatment of several conditions where these cells play a pathological role. It is widely used in the management of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), where it helps to control disease progression, reduce tumor burden, and improve patient outcomes. Additionally, its immunosuppressive effects are harnessed in autoimmune diseases such as rheumatoid arthritis (RA) and certain vasculitides, where it helps to reduce inflammation and disease activity by eliminating autoreactive B cells. The specific dosage and treatment regimen are tailored to the patient's condition and response.

Uses

• Treatment of non-Hodgkin's lymphoma (NHL)
• Management of chronic lymphocytic leukemia (CLL)
• Treatment of rheumatoid arthritis (RA)
• Management of certain autoimmune vasculitides

Directions For Use

Administer intravenously under strict medical supervision. Dosage and infusion rate are determined by the treating physician based on the specific indication.

Benefits

• Targets and depletes CD20-positive B cells
• Effective in various B-cell lymphomas and leukemias
• Reduces inflammation and disease activity in autoimmune conditions
• Improves patient survival in certain cancers
• Can be used as monotherapy or in combination regimens
• Well-characterized efficacy and safety profile

Side Effects

• Infusion-related reactions (fever, chills, rash)
• Fatigue
• Headache
• Nausea
• Diarrhea
• Neutropenia (low white blood cell count)
• Increased risk of infections
• Progressive multifocal leukoencephalopathy (PML) (rare)
• Tumor lysis syndrome
• Cardiac events
• Hepatitis B reactivation
• Mucocutaneous reactions

Safety Measures

• Alcohol - No direct interaction with alcohol, but alcohol can suppress the immune system, which is already affected by this medication. Avoid excessive alcohol consumption.
• Pregnancy - Contraindicated during pregnancy due to the risk of B-cell depletion in the fetus. Women of childbearing potential must use effective contraception during and for 12 months post-treatment.
• Breastfeeding - Not recommended during breastfeeding as it may be excreted in breast milk and could cause B-cell depletion in the infant. Discontinue breastfeeding.
• Liver - Use with caution in patients with severe liver impairment. Monitor for hepatitis B reactivation, especially in carriers.
• Kidney - No specific dosage adjustment required for kidney impairment. However, monitor for tumor lysis syndrome in patients with high tumor burden.
• Lung - Can cause severe pulmonary reactions, including interstitial lung disease. Monitor for new or worsening respiratory symptoms and discontinue if severe lung toxicity occurs.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.